Atossa Therapeutics FY2025; R&D expense climbs to $21.2 million; clinical and non-clinical trial expense rises 60% to $16.2 million

Reuters03-26
Atossa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025; R&D expense climbs to $21.2 million; clinical and non-clinical trial expense rises 60% to $16.2 million
  • $(Z)$-endoxifen is being evaluated in metastatic, neoadjuvant, adjuvant, and breast cancer risk-reduction clinical settings, and it is also being explored for rare diseases including Duchenne muscular dystrophy and McCune-Albright syndrome.
  • In a peer-reviewed publication and scientific presentation, Atossa described a hypothesized therapeutic role for (Z)-endoxifen in Duchenne muscular dystrophy, including symptomatic female carriers.
  • The publication outlines potential mechanisms relevant to dystrophic muscle, including estrogen-receptor modulation and allosteric inhibition of PKC-β1.
  • The document does not specify whether any clinical trial results have already been presented or when future results will be presented.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-124393), on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment